The Use of Complementary and Alternative Medicine Among Patients with Inflammatory Bowel Disease Is Associated with Reduced Health-Related Quality of Life

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2016 Dec 23

PMID 28003821

Citations 5

Authors

Randi Opheim

Marte Lie Hoivik

Tomm Bernklev

Lars-Petter Jelsness-Jorgensen

Bjorn Moum

Affiliations

Soon will be listed here.

Abstract

Complementary and alternative medicine (CAM) use among patients with inflammatory bowel disease (IBD) is common. The aim of this study was to explore associations between CAM use and health-related quality of life (HRQoL) as well as identifying whether sociodemographic factors, disease activity, and personal resources (self-efficacy) influence HRQoL scores in users and nonusers of CAM. Measures included sociodemographic and disease-related data, the International-CAM Questionnaire, and General Self-Efficacy Scale. A univariate analysis of variance was used to assess the association between CAM use and HRQoL. The associations between clinical, demographic, and personal factors and HRQoL were examined through linear regression analyses. CAM users had statistically significant lower SF-36 scores compared to nonusers and the background population. Nonusers scored significantly lower compared to the background population in two out of the eight SF-36 dimensions. Independent of CAM use, disease activity had a negative impact and self-efficacy had a positive impact on HRQoL. HRQoL in CAM users with IBD was significantly lower compared to nonusers and the background population. Independent of CAM use, disease activity was negatively associated with HRQoL. Self-efficacy had a positive impact on the mental health dimensions in both CAM users and nonusers.

Citing Articles

Use of Complementary and Alternative Medicine by Greek Patients with Inflammatory Bowel Disease.

Triantafillidis J, Gikas A, Kontrarou G, Konstantoulakis M, Papalois A Nutrients. 2024; 16(21).

PMID: 39519512 PMC: 11547556. DOI: 10.3390/nu16213679.

Use of Complementary and Alternative Medicine in Patients with Rare Bone Diseases and Osteoporosis.

Kocijan R, Medibach A, Lechner L, Haschka J, Kocijan A, Kraus D Nutrients. 2024; 16(6).

PMID: 38542726 PMC: 10974349. DOI: 10.3390/nu16060816.

Use of Complementary and Alternative Medicine and Its Relationship with Health-Related Quality of Life (HRQOL) in Patients with Type 2 Diabetes Mellitus.

Mori Y, Daikuhara H, Oshima T, Suzuki H, Okada S, Miyatake N Epidemiologia (Basel). 2023; 4(1):53-59.

PMID: 36810452 PMC: 9944063. DOI: 10.3390/epidemiologia4010005.

Evaluation of Anticolitis and Antioxidant Properties of (Bixaceae) Leaf Hydroethanolic Extract on Acetic Acid-Induced Ulcerative Colitis in Rats.

Fokam Tagne M, Kom B, Foyet Fondjo A, Noubissi P, Talom Tangue B, Gaffo E Curr Ther Res Clin Exp. 2022; 97:100685.

PMID: 36212166 PMC: 9539784. DOI: 10.1016/j.curtheres.2022.100685.

Self-management using crude herbs and the health-related quality of life among adult patients with hypertension living in a suburban setting of Malaysia.

Joachimdass R, Subramaniam K, Sit N, Lim Y, Hai Teo C, Jenn Ng C PLoS One. 2021; 16(9):e0257336.

PMID: 34506588 PMC: 8432735. DOI: 10.1371/journal.pone.0257336.

References

Mountifield R, Andrews J, Mikocka-Walus A, Bampton P . Doctor communication quality and Friends' attitudes influence complementary medicine use in inflammatory bowel disease. World J Gastroenterol. 2015; 21(12):3663-70. PMC: 4375592. DOI: 10.3748/wjg.v21.i12.3663. View

Loge J, Kaasa S . Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998; 26(4):250-8. View

Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S . Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A:5A-36A. DOI: 10.1155/2005/269076. View

Hoivik M, Moum B, Solberg I, Cvancarova M, Hoie O, Vatn M . Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis. 2011; 18(8):1540-9. DOI: 10.1002/ibd.21863. View

Kaboli P, Doebbeling B, Saag K, Rosenthal G . Use of complementary and alternative medicine by older patients with arthritis: a population-based study. Arthritis Rheum. 2001; 45(4):398-403. DOI: 10.1002/1529-0131(200108)45:4<398::AID-ART354>3.0.CO;2-I. View

Weizman A, Ahn E, Thanabalan R, Leung W, Croitoru K, Silverberg M . Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 35(3):342-9. DOI: 10.1111/j.1365-2036.2011.04956.x. View

Langmead L, Chitnis M, Rampton D . Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis. 2002; 8(3):174-9. DOI: 10.1097/00054725-200205000-00003. View

Ware Jr J, Gandek B . Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998; 51(11):903-12. DOI: 10.1016/s0895-4356(98)00081-x. View

Li F, Verhoef M, Best A, Otley A, Hilsden R . Why patients with inflammatory bowel disease use or do not use complementary and alternative medicine: a Canadian national survey. Can J Gastroenterol. 2005; 19(9):567-73. DOI: 10.1155/2005/943547. View

10.

Huppertz-Hauss G, Hoivik M, Jelsness-Jorgensen L, Henriksen M, Hoie O, Jahnsen J . Health-related Quality of Life in Patients with Inflammatory Bowel Disease 20 Years After Diagnosis: Results from the IBSEN Study. Inflamm Bowel Dis. 2016; 22(7):1679-87. DOI: 10.1097/MIB.0000000000000806. View

11.

Cohen J . A power primer. Psychol Bull. 2009; 112(1):155-9. DOI: 10.1037//0033-2909.112.1.155. View

12.

Hilsden R, Verhoef M, Rasmussen H, Porcino A, deBruyn J . Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010; 17(2):655-62. DOI: 10.1002/ibd.21360. View

13.

Oxelmark L, Lindberg A, Lofberg R, Sternby B, Eriksson A, Almer S . Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study. Eur J Gastroenterol Hepatol. 2016; 28(11):1320-8. PMC: 5051534. DOI: 10.1097/MEG.0000000000000710. View

14.

Stjernman H, Tysk C, Almer S, Strom M, Hjortswang H . Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease. Eur J Gastroenterol Hepatol. 2011; 23(8):671-9. DOI: 10.1097/MEG.0b013e328346f622. View

15.

Quandt S, Verhoef M, Arcury T, Lewith G, Steinsbekk A, Kristoffersen A . Development of an international questionnaire to measure use of complementary and alternative medicine (I-CAM-Q). J Altern Complement Med. 2009; 15(4):331-9. PMC: 3189003. DOI: 10.1089/acm.2008.0521. View

16.

Jelsness-Jorgensen L, Bernklev T, Henriksen M, Torp R, Moum B . Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 33(1):106-14. DOI: 10.1111/j.1365-2036.2010.04498.x. View

17.

Huppertz-Hauss G, Hoivik M, Langholz E, Odes S, Smastuen M, Stockbrugger R . Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis. 2015; 21(2):337-44. PMC: 4345967. DOI: 10.1097/MIB.0000000000000272. View

18.

van der Have M, Minderhoud I, Kaptein A, Leenders M, Siersema P, Fidder H . Substantial impact of illness perceptions on quality of life in patients with Crohn's disease. J Crohns Colitis. 2012; 7(8):e292-301. DOI: 10.1016/j.crohns.2012.11.002. View

19.

Huo N, Ray G, Mehta S, LoBello S . Complementary and alternative medicine use among people with asthma and health-related quality of life. J Asthma. 2014; 52(3):308-13. DOI: 10.3109/02770903.2014.963867. View

20.

Walmsley R, Ayres R, Pounder R, Allan R . A simple clinical colitis activity index. Gut. 1998; 43(1):29-32. PMC: 1727189. DOI: 10.1136/gut.43.1.29. View